ArticleScientific reports2025
Seeding Alzheimer's disease-associated tau pathology in MAPT knock-in primary neurons causes early axonopathy and synaptic dysfunction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Large-Scale Neural Recording Technologies for Investigating Circuit Dysfunction and Functional Biomarker Discovery in Animal Models of Alzheimer's Disease.International journal of molecular sciences · 2026Review
- Aberrant medial entorhinal cortex dynamics link tau pathology to spatial memory impairment.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The progressive accumulation of pathological tau is a hallmark of Alzheimer's disease (AD). The bulk of existing in vitro and in vivo evidence suggests that pathological tau forms can seed further aggregation of the protein. However, many of the subsequent functional consequences following the formation of pathogenic tau aggregates are not yet fully understood. Here, we utilized the tau seeding phenomenon to induce the formation of pathogenic tau and identify intracellular consequences in a neuron culture model of AD-associated tauopathy. Primary neurons from human tau knock-in (MAPT-KI) mice were seeded with human AD brain-derived insoluble tau (AD-tau). Microscopy and biochemical assays were used to characterize the pathological tau species formed, as well as the extent of neuronal, axonal and synaptic degeneration in seeded MAPT-KI neurons. In addition, high-density microelectrode arrays were used to assess synaptic functionality in seeded MAPT-KI neuron cultures. Human-derived AD-tau seeded intracellular endogenous tau inclusions that contained AD-associated modifications (i.e. phosphorylation at the PHF1, AT8, and pS422 antibody epitopes) and adopted multiple pathogenic conformations (i.e. oligomers and exposure of an N-terminal phosphatase activating domain; PAD). Tau inclusions, containing pS422 + and PAD-exposed tau, colocalized with active glycogen synthase kinase 3β (the kinase involved in PAD-mediated axonal transport impairment) and accumulations of axonal transport cargo proteins (i.e. synaptophysin and amyloid precursor protein) in dystrophic axons. While there was no overt axonal degeneration or cell loss, intact excitatory synapses were reduced in the AD-tau neurons. Neuron cultures treated with AD-tau exhibited an N-methyl-D-aspartate receptor-dependent increase in network burst frequency when activated with glutamate as measured through high-density microelectrode arrays. Together, the data demonstrate that the AD-tau seeded MAPT-KI neuron model exhibits features associated with neuronal dysfunction resembling those that occur early in human disease (i.e. axonal pathology and dystrophy, hyperexcitability and hypersynchrony), without causing overt neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.